免疫检查点抑制剂在肺癌、黑色素瘤等多种肿瘤治疗方面取得了客观疗效并改善了生存,多种免疫检查点抑制剂获得美国食品与药物管理局批准上市并应用于多种肿瘤的免疫治疗中。在肾癌、膀胱癌及前列腺癌等常见泌尿系肿瘤,免疫检查点抑制剂也取得了良好的治疗效果。本文对免疫检查点抑制剂在常见泌尿系肿瘤的临床研究结果予以综述。 Immune checkpoint inhibitors have achieved objective efficacy and improved survival in a variety of oncology treatments such as lung cancer and melanoma. Various immune checkpoint inhibitors have been approved by the U.S. Food and Drug Administration for immunotherapy in a variety of tumors in. In kidney cancer, bladder cancer and prostate cancer and other common urinary tumors, immune checkpoint inhibitors have also made a good therapeutic effect. This article reviews the clinical findings of immune checkpoint inhibitors in common urological tumors.